Sano
Sano Genetics provides a comprehensive platform for clinical trial recruitment, genetic testing, and long-term patient engagement in precision medicine research. The platform automates workflows across the research process, offering services including study design and protocol development, recruitment support through online campaigns and patient advocacy networks, prescreening and digital consent, electronic medical…
Funding snapshot
About
Sano Genetics provides a comprehensive platform for clinical trial recruitment, genetic testing, and long-term patient engagement in precision medicine research. The platform automates workflows across the research process, offering services including study design and protocol development, recruitment support through online campaigns and patient advocacy networks, prescreening and digital consent, electronic medical record retrieval, at-home saliva DNA testing with end-to-end logistics and genetic counseling, and customized patient engagement programs. Sano supports multi-country, multi-language programs across disease areas including lupus, Parkinson's, MASH, ALS, and Long COVID. The platform is ISO27001 certified, HIPAA and GDPR compliant, with options for dedicated cloud infrastructure. Founded in 2016 and headquartered in London, United Kingdom, Sano has raised approximately $26.5 million in Series A funding from investors including Plural, MMC Ventures, Y Combinator, and Cambridge Enterprise.
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine
Team background
College Wise > University of Cambridge, University College London
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.